Therapeutic medications against diabetes: What we have and what we expect

被引:50
作者
Hu, Cheng [1 ,2 ]
Jia, Weiping [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Key Clin Ctr Metab Dis, Shanghai Diabet Inst,Shanghai Key Lab Diabet Mell, 600 Yishan Rd, Shanghai 200233, Peoples R China
[2] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, South Campus,6600 Nanfeng Rd, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
Diabetes; Treatment; Drug delivery; Natural product; GLUCAGON-LIKE PEPTIDE-1; COTRANSPORTER; 2; INHIBITORS; ENCAPSULATES SUBCUTANEOUS IMPLANTS; INADEQUATE GLYCEMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; BLOOD-GLUCOSE CONCENTRATION; GLP-1 RECEPTOR AGONISTS; BETA-CELL FUNCTION; ORAL DELIVERY; INSULIN DELIVERY;
D O I
10.1016/j.addr.2018.11.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetes has become one of the largest global health and economic burdens, with its increased prevalence and high complication ratio. Stable and satisfactory blood glucose control are vital to reduce diabetes-related complications. Therefore, continuous attempts have been made in antidiabetic drugs, treatment routes, and traditional Chinese medicine to achieve better disease control. New antidiabetic drugs and appropriate combinations of these drugs have increased diabetes control significantly. Besides, novel treatment routes including oral antidiabetic peptide delivery, nanocarrier delivery system, implantable drug delivery system are also pivotal for diabetes control, with its greater efficiency, increased bioavailability, decreased toxicity and reduced dosing frequency. Among these new routes, nanotechnology, artificial pancreas and islet cell implantation have shown great potential in diabetes therapy. Traditional Chinese medicine also offer new options for diabetes treatment. Our paper aim to overview these therapeutic methods for diabetes therapy. Proper combinations of these existing anti diabetic medications and searching for novel routes are both necessary for better diabetes control. (C) 2018 Published by Elsevier B.V.
引用
收藏
页码:3 / 15
页数:13
相关论文
共 181 条
  • [1] Chitosan-Modified Cationic Amino Acid Nanoparticles as a Novel Oral Delivery System for Insulin
    Abbad, Sarra
    Zhang, Zhenhai
    Waddad, Ayman Y.
    Munyendo, Were L. L.
    Lv, Huixia
    Zhou, Jianping
    [J]. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2015, 11 (03) : 486 - 499
  • [2] Dendrimers: synthesis, applications, and properties
    Abbasi, Elham
    Aval, Sedigheh Fekri
    Akbarzadeh, Abolfazl
    Milani, Morteza
    Nasrabadi, Hamid Tayefi
    Joo, Sang Woo
    Hanifehpour, Younes
    Nejati-Koshki, Kazem
    Pashaei-Asl, Roghiyeh
    [J]. NANOSCALE RESEARCH LETTERS, 2014, 9 : 1 - 10
  • [3] Mucoadhesive Polymeric Platform for Drug Delivery; A Comprehensive Review
    Agarwal, Shweta
    Aggarwal, Shikha
    [J]. CURRENT DRUG DELIVERY, 2015, 12 (02) : 139 - 156
  • [4] Application of polymeric nanoparticles and micelles in insulin oral delivery
    Alai, Milind Sadashiv
    Lin, Wen Jen
    Pingale, Shailaja Suresh
    [J]. JOURNAL OF FOOD AND DRUG ANALYSIS, 2015, 23 (03) : 351 - 358
  • [5] Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting
    Alamoudi, Reem
    Alsubaiee, Maram
    Alqarni, Ali
    Saleh, Yousef
    Aljaser, Saleh
    Salam, Abdul
    Eledrisi, Mohsen
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (06) : 349 - 354
  • [6] Standards of Medical Care in Diabetes-2014
    不详
    [J]. DIABETES CARE, 2014, 37 : S14 - S80
  • [7] [Anonymous], AM J KIDNEY DIS S1
  • [8] [Anonymous], 2021, IDF Diabetes Atlas
  • [9] [Anonymous], ADV DRUG DELIV REV
  • [10] A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
    Aroda, Vanita R.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 : 22 - 33